C4 Tx - CCCC Quarterly EPS earnings growth

Corporate company logo of C4 Therapeutics (CCCC)

Local conflicts are hindering medical research and disrupting biomaterial logistics for C4 Therapeutics, Inc. (CCCC). Quarterly growth in earnings per share reflects revenue dynamics, where the 63.30 mark captures the latest data. While challenges with Asian raw material imports limit business stability, partnerships with pharma behemoths in the field of protein degradation create a promising foundation for commercial success.

c4therapeutics.com (CCCC) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for C4 Therapeutics, Inc.

- share price and consensus valuation forecast:
Fundamental company valuation:c4therapeutics.com - CCCC
Flagship merchandise of c4therapeutics.com

This indicator measures the dynamics of net earnings per share, reflecting the actual speed of financial result capitalization. For C4 Therapeutics, Inc. (CCCC), this calculation is critical, as a high proportion of R&D expenses creates a sharp contrast with the future profitability of patents. By analyzing the relative growth of quarterly EPS, an investor can see the pace of the transition from losses to superprofits. The metric eliminates price noise, focusing instead on fundamental income. A positive trend would confirm the commercial scalability of the developments.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Biosciences|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (cullinanoncology.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immuneering Inc. IMRX|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)